Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited ...
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today presented preclinical data for REX-8756 ...
Deal gives Vyome entry into the fast-growing market for next-generation autoimmune and inflammatory disease drugs ...
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg ...
Bank of America Global Healthcare Conference 2026 May 13, 2026 4:40 PM EDTCompany ParticipantsWilliam Meury - CEO ...
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today presented preclinical data ...
Vyome strikes deal with Impetis Biosciences, opening a $57 billion market opportunity: Our Bureau, Bengaluru Wednesday, May 13, 2026, 14:30 Hrs [IST] Vyome Holdings, Inc. has inke ...
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner of the "Genomics ...
Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ...
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemiaAdditional abstracts highlighting updates on HELIOS open label extension study of bitopertin ...
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results